Who is sponsoring NCT05935202?

NCT05935202 is sponsored by EuroBloodNet Association.

What drugs are being tested in NCT05935202?

Interventions in NCT05935202: Mitapivat sulfate.

What condition does NCT05935202 study?

NCT05935202 studies Hereditary Red Blood Cell Disorder (Disorder).

Is NCT05935202 still recruiting?

NCT05935202 is currently not yet recruiting. Last updated 26 December 2023.

Last reviewed 2023-12-26 · How we verify

NCT05935202: SATISFY

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Efficacy of Mitapivat Sulfate in Adult Patients With Erythrocyte Membranopathies

Not yet recruiting Phase 2 Last updated 26 December 2023

What this trial tests

Phase 2 trial testing Mitapivat sulfate in Hereditary Red Blood Cell Disorder (Disorder) in 25 participants. Not yet recruiting.

Timeline

21 December 2023

Primary endpoint
15 July 2025

15 December 2026

Quick facts

Lead sponsor	EuroBloodNet Association
Phase	Phase 2
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	25
Start date	21 December 2023
Primary completion	15 July 2025
Estimated completion	15 December 2026
Sites	2 locations across Denmark, Netherlands

Drugs / interventions tested

Mitapivat sulfate — full drug profile →

Conditions studied

Hereditary Red Blood Cell Disorder (Disorder) — all drugs for Hereditary Red Blood Cell Disorder (Disorder) →

Sponsor

EuroBloodNet Association

Who can join

Adults 18 to 99, any sex, with Hereditary Red Blood Cell Disorder (Disorder). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective exploratory multicentre pilot study designed to study the safety and efficacy of mitapivat in RBC membranopathies and CDAII

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Designing a single-arm phase 2 clinical trial of mitapivat for adult patients with erythrocyte membranopathies (SATISFY): a framework for interventional trials in rare anaemias - pilot study protocol.
Glenthøj A, van Beers EJ, van Wijk R, Rab MAE, et al · · 2024 · cited 2× · PMID 39079928 · DOI 10.1136/bmjopen-2023-083691
Post-translational Modifications in Proteins: Prediction Methods, Biological Functions, and Diseases.
Zhang S, Li J, Chen M, Huang H. · · 2026 · PMID 41978829 · DOI 10.1002/mco2.70729

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05935202 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by EuroBloodNet Association
Last refreshed: 26 December 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05935202.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing